Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cytokinetics (CYTK) Shares Outstanding (Diluted Average) (2020 - 2025)

Cytokinetics (CYTK) has disclosed Shares Outstanding (Diluted Average) for 8 consecutive years, with $120103.0 as the latest value for Q4 2025.

  • On a quarterly basis, Shares Outstanding (Diluted Average) changed N/A to $120103.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $120103.0, a N/A change, with the full-year FY2025 number at $120103.0, changed N/A from a year prior.
  • Shares Outstanding (Diluted Average) was $120103.0 for Q4 2025 at Cytokinetics, roughly flat from $119982.0 in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $120103.0 in Q4 2025 to a low of $71754.0 in Q2 2021.
  • A 5-year average of $97878.7 and a median of $95710.5 in 2023 define the central range for Shares Outstanding (Diluted Average).
  • Peak YoY movement for Shares Outstanding (Diluted Average): rose 19.48% in 2022, then grew 2.04% in 2023.
  • Cytokinetics' Shares Outstanding (Diluted Average) stood at $76886.0 in 2021, then grew by 16.83% to $89825.0 in 2022, then grew by 7.46% to $96524.0 in 2023, then increased by 13.89% to $109932.0 in 2024, then increased by 9.25% to $120103.0 in 2025.
  • Per Business Quant, the three most recent readings for CYTK's Shares Outstanding (Diluted Average) are $120103.0 (Q4 2025), $119982.0 (Q3 2025), and $118979.0 (Q2 2025).